Berapakah harga Clarus Therapeutics Holdings, Inc. (CRXTQ)

Harga Clarus Therapeutics Holdings, Inc. (CRXTQ) adalah $0.0014

Apakah topi pasaran Clarus Therapeutics Holdings, Inc. (CRXTQ)

Cap pasaran Clarus Therapeutics Holdings, Inc. (CRXTQ) adalah $72.83K

Clarus Therapeutics Holdings, Inc. (CRXTQ) Dividen

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

Tahun	Dividen (diselaraskan untuk pemecahan saham)	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Dividen (diselaraskan untuk pemecahan saham)

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Tahun	Dividen	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Dividen

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Jumlah pembayaran dividen	Negara
Eli Lilly and Company LLY.US	215.00%	US
Johnson & Johnson JNJ.US	225.00%	US
AbbVie Inc. ABBV.US	53.00%	US
Roche Holding AG RO.SW	33.00%	CH
Merck & Co., Inc. MRK.US	223.00%	US

Syarikat

Jumlah pembayaran dividen

Negara